



## ASX Release

### **Avexa board member Steven Crowley resigns following appointment as Executive Director at Janssen-Cilag**

**Melbourne, Australia, Friday 5 November 2010**

Australian biotechnology company Avexa Limited [ASX:AVX] today announced the resignation of Mr Steven Crowley from the Avexa board.

Mr Crowley has been appointed Executive Director at Janssen-Cilag Australia, a leading research-based pharmaceutical company. His new position precludes him from continuing to serve on public company boards, such as the Avexa board, because of possible conflicts of interest.

Joe Baini, Chairman of Avexa, said: "On behalf of the board, I would like to thank Steve for his valuable contribution and support and congratulate him on his appointment to Janssen-Cilag Australia. We wish him all the very best for the future."

#### **About Avexa Limited**

Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and commercialisation of small molecules for the treatment of infectious diseases. Avexa's key projects include apricitabine (ATC) for the treatment of drug-resistant HIV, an HIV integrase program, an HCV polymerase program and an antibiotic program for antibiotic-resistant bacterial infections.

#### **For more information:**

**Joe Baini**  
**Avexa Chairman**  
**Ph: +61 3 9208 4300**

**Stephen Kerr**  
**Avexa Company Secretary**  
**Ph: +61 3 9208 4300**

**Richard Allen**  
**Oxygen Financial Public Relations**  
**Ph: + 61 3 9915 6341**